- Hospitaler/Afdelinger Se de enkelte afdelingers forskningsprofil
- Forskere Søg forskere og deres videnskabelige arbejde
- Publikationer Publikationer med forskere fra Region Hovedstaden
- Forskningsprojekter Søg projekter/clinical trials i Region Hovedstaden
- Aktiviteter Med forskere fra Region Hovedstaden
Forskning
Udskriv
Switch language
Region Hovedstaden
- en del af Københavns Universitetshospital
Udgivet
"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"
Publikation: Bidrag til tidsskrift › Letter › Forskning › peer review
Harvard
Rasmussen, B, Göhring, G, Bernard, E, Nilsson, L, Tobiasson, M, Jädersten, M, Garelius, H, Dybedal, I, Grønbaek, K, Ejerblad, E, Lorenz, F, Flogegård, M, Marcher, CW, Öster Fernström, A, Cavelier, L, Papaemmanuil, E, Ebeling, F, Kittang, AO, Nørgaard, JM, Saft, L, Möllgård, L & Hellström-Lindberg, E 2022, '"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"', Leukemia, bind 36, nr. 5, s. 1436-1439. https://doi.org/10.1038/s41375-022-01537-w
APA
Rasmussen, B., Göhring, G., Bernard, E., Nilsson, L., Tobiasson, M., Jädersten, M., Garelius, H., Dybedal, I., Grønbaek, K., Ejerblad, E., Lorenz, F., Flogegård, M., Marcher, C. W., Öster Fernström, A., Cavelier, L., Papaemmanuil, E., Ebeling, F., Kittang, A. O., Nørgaard, J. M., ... Hellström-Lindberg, E. (2022). "Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)". Leukemia, 36(5), 1436-1439. https://doi.org/10.1038/s41375-022-01537-w
CBE
Rasmussen B, Göhring G, Bernard E, Nilsson L, Tobiasson M, Jädersten M, Garelius H, Dybedal I, Grønbaek K, Ejerblad E, Lorenz F, Flogegård M, Marcher CW, Öster Fernström A, Cavelier L, Papaemmanuil E, Ebeling F, Kittang AO, Nørgaard JM, Saft L, Möllgård L, Hellström-Lindberg E. 2022. "Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)". Leukemia. 36(5):1436-1439. https://doi.org/10.1038/s41375-022-01537-w
MLA
Rasmussen, Bengt o.a.. ""Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"". Leukemia. 2022, 36(5). 1436-1439. https://doi.org/10.1038/s41375-022-01537-w
Vancouver
Rasmussen B, Göhring G, Bernard E, Nilsson L, Tobiasson M, Jädersten M o.a. "Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)". Leukemia. 2022 maj;36(5):1436-1439. https://doi.org/10.1038/s41375-022-01537-w
Author
Bibtex
@article{4a77bca6b71f4f47944b43b4b8e2d270,
title = "{"}Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q){"}",
keywords = "Azacitidine, Chromosome Deletion, Chromosomes, Human, Pair 5/genetics, Humans, Karyotype, Lenalidomide/therapeutic use, Leukemia, Myeloid, Acute/drug therapy, Myelodysplastic Syndromes/drug therapy",
author = "Bengt Rasmussen and Gudrun G{\"o}hring and Elsa Bernard and Lars Nilsson and Magnus Tobiasson and Martin J{\"a}dersten and Hege Garelius and Ingunn Dybedal and Kirsten Gr{\o}nbaek and Elisabeth Ejerblad and Fryderyk Lorenz and Max Flogeg{\aa}rd and Marcher, {Claus Werenberg} and {{\"O}ster Fernstr{\"o}m}, Annette and Lucia Cavelier and Elli Papaemmanuil and Freja Ebeling and Kittang, {Astrid Olsnes} and N{\o}rgaard, {Jan Maxwell} and Leonie Saft and Lars M{\"o}llg{\aa}rd and Eva Hellstr{\"o}m-Lindberg",
year = "2022",
month = may,
doi = "10.1038/s41375-022-01537-w",
language = "English",
volume = "36",
pages = "1436--1439",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "5",
}
RIS
TY - JOUR
T1 - "Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"
AU - Rasmussen, Bengt
AU - Göhring, Gudrun
AU - Bernard, Elsa
AU - Nilsson, Lars
AU - Tobiasson, Magnus
AU - Jädersten, Martin
AU - Garelius, Hege
AU - Dybedal, Ingunn
AU - Grønbaek, Kirsten
AU - Ejerblad, Elisabeth
AU - Lorenz, Fryderyk
AU - Flogegård, Max
AU - Marcher, Claus Werenberg
AU - Öster Fernström, Annette
AU - Cavelier, Lucia
AU - Papaemmanuil, Elli
AU - Ebeling, Freja
AU - Kittang, Astrid Olsnes
AU - Nørgaard, Jan Maxwell
AU - Saft, Leonie
AU - Möllgård, Lars
AU - Hellström-Lindberg, Eva
PY - 2022/5
Y1 - 2022/5
KW - Azacitidine
KW - Chromosome Deletion
KW - Chromosomes, Human, Pair 5/genetics
KW - Humans
KW - Karyotype
KW - Lenalidomide/therapeutic use
KW - Leukemia, Myeloid, Acute/drug therapy
KW - Myelodysplastic Syndromes/drug therapy
UR - http://www.scopus.com/inward/record.url?scp=85126099436&partnerID=8YFLogxK
U2 - 10.1038/s41375-022-01537-w
DO - 10.1038/s41375-022-01537-w
M3 - Letter
C2 - 35277655
VL - 36
SP - 1436
EP - 1439
JO - Leukemia
JF - Leukemia
SN - 0887-6924
IS - 5
ER -
ID: 77931366